Just saw Arcutis announced their Phase 2 results for ZORYVE cream in infants with atopic dermatitis and it's looking pretty solid. About 58% of the babies in their study hit that EASI-75 improvement mark at 4 weeks, and the safety profile held up with no new concerns. They already got FDA approval for the 2-5 year age group last year, so now they're planning to push for approval in the younger kids (3 months to under 2 years) next quarter. Stock was down a bit on Friday though, sitting at $25.37. Interesting to see if this dermatitis treatment expansion plays out - could be a meaningful move for pediatric atopic dermatitis care if they get the green light. What's your take on biotech plays like this?